Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

This study has been completed.
Information provided by (Responsible Party):
Navidea Biopharmaceuticals Identifier:
First received: April 14, 2010
Last updated: June 6, 2013
Last verified: June 2013
Results First Received: April 13, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Conditions: Breast Cancer
Intervention: Drug: Lymphoseek

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Lymphoseek, Lymphatic Mapping, Injection Melanoma and breast cancer patients to receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.

Participant Flow:   Overall Study
    Lymphoseek, Lymphatic Mapping, Injection
STARTED   163 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Of the 163 participants who enrolled in the trial, 153 were administered the study agent, Lymphoseek, and therefore this participant number is used for the baseline analysis.

Reporting Groups
Lymphoseek Enrolled patients who were administered any injection of Lymphoseek.

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   101 
>=65 years   52 
[Units: Years]
Mean (Standard Deviation)
 59.3  (12.4) 
[Units: Participants]
Female   104 
Male   49 
Region of Enrollment 
[Units: Participants]
United States   153 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Concordance of Blue Dye and Lymphoseek   [ Time Frame: Surgery after injections of Lymphoseek and blue dye ]

2.  Secondary:   Reverse Concordance of Blue Dye and Lymphoseek   [ Time Frame: Surgery after injections of Lymphoseek and blue dye ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

  More Information